331. Idiopathic multicentric castleman disease Clinical trials / Disease details
Clinical trials : 33 / Drugs : 46 - (DrugBank : 25) / Drug target genes : 31 - Drug target pathways : 155
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100048364 | 2021-09-01 | 2021-07-06 | A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease | A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease | Castleman disease | Treatment group:Rituximab+lenalidomide; | Department of Hematology, Jiangsu Provincial People's Hospital | NULL | Pending | 14 | 90 | Both | Treatment group:20; | Phase 4 | China |
| 2 | NCT04585893 (ClinicalTrials.gov) | June 22, 2021 | 10/9/2020 | Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi | LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial | Multicentric Castleman Disease | Drug: Rituximab;Drug: Etoposide | UNC Lineberger Comprehensive Cancer Center | Fogarty International Center of the National Institute of Health | Recruiting | 18 Years | N/A | All | 27 | Phase 2 | Malawi |
| 3 | NCT03864419 (ClinicalTrials.gov) | October 24, 2019 | 1/3/2019 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda | Burkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell Lymphoma | Biological: Rituximab and Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotrexate;Drug: Doxorubicin;Drug: Doxorubicin Hydrochloride;Drug: Prednisone;Drug: Etoposide;Biological: Rituximab | Fred Hutchinson Cancer Research Center | NULL | Recruiting | 2 Years | N/A | All | 40 | Phase 1 | Uganda;United States |
| 4 | NCT02228512 (ClinicalTrials.gov) | August 15, 2014 | 27/8/2014 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) | Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;Primary Effusion Lymphoma | Drug: Pomalidomide;Drug: Rituximab;Drug: Prednisone;Drug: Etoposide;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide | National Cancer Institute (NCI) | NULL | Withdrawn | 18 Years | 99 Years | All | 0 | Phase 1/Phase 2 | United States |
| 5 | NCT00092222 (ClinicalTrials.gov) | October 28, 2004 | 21/9/2004 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity | Lymphoproliferative Disorder;HHV-8;Malignancy;HIV | Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation Only | National Cancer Institute (NCI) | NULL | Recruiting | 18 Years | N/A | All | 80 | Phase 2 | United States |
| 6 | NCT00127569 (ClinicalTrials.gov) | May 2003 | 4/8/2005 | Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy | Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB) | HIV Infections;Giant Lymph Node Hyperplasia | Drug: Rituximab | French National Agency for Research on AIDS and Viral Hepatitis | Hoffmann-La Roche | Terminated | 18 Years | N/A | Both | 25 | Phase 2 | NULL |